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OBJECTIVE — Diabetes is increasingly common in cystic ﬁbrosis, but little information
describing its inﬂuence on mortality exists. Using national U.K. data, in this study we document
diabetes-speciﬁc mortality rates, estimate the impact of diabetes on survival, and estimate pop-
ulation-attributable fractions.
RESEARCH DESIGN AND METHODS — This retrospective cohort study identiﬁed
8,029 individuals aged 0–65 years from the U.K. Cystic Fibrosis Registry (1996–2005). A total
of 5,892 patients were included in analyses of mortality rates, and 4,234 were included in
analyses of risk factors. We calculated age-adjusted mortality rates using Poisson regression,
standardizedmortalityratiosusingthepopulationofEnglandandWales,andrelativerisksusing
proportional hazards modeling.
RESULTS — During 17,672 person-years of follow-up, 393 subjects died. The age-adjusted
mortality rate was 1.8 per 100 person-years (95% CI 1.6–2.0). The age-adjusted mortality rates
per 100 person-years were 2.0 (1.8–2.4) in female subjects and 1.6 (1.4–1.9) in male subjects,
and 4.2 (3.4–5.1) in individuals with diabetes vs. 1.5 (1.3–1.7) in those without diabetes.
Independent risk factors for death included diabetes (hazard ratio 1.31 [95% CI 1.03–1.67],
female sex (1.71 [1.36–2.14]) plus poorer pulmonary function, lower BMI, Burkholderia cepacia
infection, absence of Staphylococcus aureus infection, allergic bronchopulmonary aspergillosis,
liver disease, prior organ transplantation, and corticosteroid use.
CONCLUSIONS — Individualswithcysticﬁbrosisdieearlieriftheyhavediabetes,which,if
delayed or better treated, might reasonably extend survival; this hypothesis merits testing.
Diabetes Care 33:311–316, 2010
C
ystic ﬁbrosis is the most common
autosomal recessive disease leading
to premature death in white popu-
lations. Because of improvements in care,
bothsurvival,withalifeexpectancytothe
mid-30s,and,asaconsequence,theprev-
alence of complications have increased
dramatically (1–3). The inﬂuence of birth
year and sex on mortality has been de-
scribed in the British cystic ﬁbrosis pop-
ulation (2,4), but little is documented
about the association between complica-
tions and speciﬁcally diabetes and
mortality.
The majority of patients with cystic
ﬁbrosis die of respiratory complications.
In patients with cystic ﬁbrosis, there is a
high incidence of diabetes (5), which has
been shown to increase the risk of death
in the U.S. (6). Yet, little information ex-
ists worldwide to document the absolute
mortality rates associated with diabetes in
cystic ﬁbrosis. Using national registry
data, in this study we estimate the impact
of diabetes on survival in adults and chil-
dren with cystic ﬁbrosis in Britain, taking
into account recognized and potential
risk factors for death. We document mor-
tality rates, estimate the risk increase as-
sociated with diabetes, and calculate the
population-attributablefraction(PAF)for
diabetes associated with death.
RESEARCH DESIGN AND
METHODS— This retrospective co-
hort study identiﬁed 8,029 individuals
aged 0–65 years registered on the U.K.
Cystic Fibrosis Registry from 1996 to
2005. The registry, administered by the
U.K. Cystic Fibrosis Trust, records infor-
mation about the health and treatment of
patients from birth (7). Data are collected
from 50 British cystic ﬁbrosis care centers
in a standardized anonymous fashion af-
ter patient consent. Data gathering is an
ongoingeffort,andtheregistryisupdated
annually.
Of 8,029 patients with cystic ﬁbrosis,
6,678 had baseline data comprising reg-
istration followed by at least one clinic
visit and an annual review within the
same calendar year. We considered the
ﬁrst visit as the start of follow-up. We ex-
cluded 786 individuals without further
follow-up, leaving 5,892 patients for
analyses of mortality rates. Of these, we
included 4,234 individuals with com-
plete data in analyses of risk factors for
mortality. Individuals with complete data
were older because of the difﬁculties in
testingpulmonaryfunctioninyoungchil-
dren and were more likely to be white.
End point and potential risk factors
Information on whether a patient had
died and the date of death were taken
from the cystic ﬁbrosis registry. The reg-
istry did not contain information about
individuals’ identities, and we could not
obtain death certiﬁcates.
Potential risk factors for death mea-
sured at baseline included age, sex, eth-
nicity, BMI, pulmonary function,
diabetes, respiratory infections, class of
cystic ﬁbrosis transmembrane conduc-
tance regulator (CFTR) alleles, diagnosis
of cystic ﬁbrosis by neonatal screening,
prior organ transplantation, and other
medicalinterventionsasdescribedbelow.
We categorized ethnicity as white or non-
white. BMI was calculated as weight in
kilograms divided by the square of height
inmeters,andwecomputedBMIZscores
usingaU.K.referencepopulation(8).We
coded CFTR alleles into ﬁve classes re-
ﬂecting, for CFTR protein, defective pro-
duction, processing, regulation,
conductance, and quantity (9) and fur-
thercategorizedashigh(classesI–III)and
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(5,10). Pulmonary function was mea-
sured as forced expiratory volume at 1 s
(FEV1) and forced vital capacity, both ex-
pressed as percentage of predicted (11).
We considered diabetes present if a pa-
tient had at least one of the following: 1)
diagnosed diabetes, 2) treatment with in-
sulin or oral hypoglycemic drugs, or 3)
values consistent with diabetes on oral
glucose tolerance testing per World
Health Organization criteria. We consid-
ered an individual infected if bacteria or
fungi were cultured at baseline from spu-
tum or a throat swab or if a physician had
diagnosed chronic infection. Organisms
included Pseudomonas aeruginosa, Staphy-
lococcus aureus, Burkholderia cepacia com-
plex, Haemophilus inﬂuenzae, methicillin-
resistant S. aureus, and Aspergillus
fumigatus.Allergicbronchopulmonaryas-
pergillosis (ABPA) was diagnosed clini-
cally. We deﬁned liver disease as one of
the following: 1) abnormal liver function
tests, 2) cirrhosis with portal hyperten-
sion, or 3) use of supplementary bile ac-
ids. Pancreatic insufﬁciency was deﬁned
as supplementation with oral pancreatic
enzymes. We deﬁned corticosteroid use
as any oral or inhaled use in the year be-
fore baseline and nutritional supplemen-
tation as feedings of any kind, ranging
from oral supplements to parenteral
feedings.
Statistical analyses
We calculated mortality rates expressed
per100persons/yearin5,892individuals
as the number of deaths divided by total
survival time, i.e., from registration to
deathorthelastclinicvisit.UsingPoisson
regression, we age-adjusted mortality
rates separately for male and female sub-
jects and for those with and without dia-
betes. We stratiﬁed mortality rates by 10-
year age-groups. We calculated directly
standardized mortality rates and stan-
dardized mortality ratios (SMRs) using as
a standard the 2005 population of En-
gland and Wales (12).
We tested for differences in baseline
characteristics between those who died
andthosewhosurvivedusinga
2testfor
categorical variables and t tests or
Kruskal-Wallis tests for normally distrib-
uted or nonnormally distributed contin-
uous variables. We identiﬁed risk factors
for mortality among the 4,234 patients
with complete data using Cox propor-
tional regression; the hazard ratio (HR)
was used to estimate the relative risk. We
evaluated proportional hazards assump-
tions examining Kaplan-Meier survival
curves for categorical variables; none vio-
latedtheassumptions.Wechosevariables
for multivariate modeling if associated
with mortality in univariate Cox regres-
sion analyses (P  0.05) or if a factor had
been previously reported to be associated
with the risk of death in cystic ﬁbrosis,
e.g., sex and S. aureus. We chose the ﬁnal
model using a stepwise approach and
likelihood ratios. We tested for two-way
interactions between diabetes and each
risk factor in the ﬁnal multivariate model.
We calculated PAF as (13)
PAF 
pd(RR  1)
RR
where pd is the proportion of deaths of
those exposed to a risk factor (e.g., diabe-
tes) and RR is the adjusted HR from mul-
tivariate proportional hazards modeling.
We coded percent predicted FEV1,
BMI Z score, and age as continuous vari-
ables in proportional hazards models and
as binary variables around the approxi-
mate medians (70% for FEV1, 0.23
forBMIZscore,and16yearsforage)to
calculate PAFs. Analyses were performed
using Access (Microsoft), R (R Develop-
ment Core Team, 2007), and STATA
(StataCorp).
RESULTS
Study population
Of the 5,892 individuals, 3,155 (54%)
were male. The median age at baseline
was 13.4 years (interquartile range 6.9–
21.8). Of 4,234 individuals with data on
risk factors, an equivalent proportion
were male. The median age was 16.0 and
97% were white.
Mortality rates and standardized
mortality ratios
The median follow-up time was 2.9 years
(interquartile range 1.9–4.0). In 17,672
person-years, 393 subjects died. The
mortality rates increased with increasing
age (Fig. 1). The crude annual mortality
rate was 2.2 (95% CI 2.0–2.5) per 100
person-years. The age-adjusted mortality
rate for the cohort was 1.8 per 100 per-
son-years (1.6–2.0). Female subjects had
a higher age-adjusted mortality rate at 2.0
(1.8–2.4) per 100 person-years than did
male subjects at 1.6 (1.4–1.9) per 100
person-years.
Individualswithdiabeteshadconsid-
erably higher age-adjusted mortality rates
at 4.2 (95% CI 3.4–5.1) per 100 person-
years than those without diabetes at 1.5
(1.3–1.7) per 100 person-years. Patients
withdiabeteshadhigherabsolutemortal-
Figure 1—Mortality rates with 95% CI by age and sex in patients with cystic ﬁbrosis.  , Male
patients; f, female patients. *P  0.05, difference between sexes.
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tive difference in children 10 years old
at baseline (P  0.09) (Fig. 2).
Crudeanddirectlystandardizedmor-
tality rates expressed per 1,000 person-
years and SMRs are presented in Table 1.
The SMRs, which measure the risk of
death relative to that of the general pop-
ulation of the same age, were 55.5, 39.8,
and 84.1 for the total cohort, men, and
women, respectively. Female patients
with diabetes were 200 times more
likely to die relative to their counterparts
in the general population.
Risk factors associated with
mortality in cystic ﬁbrosis
The characteristics and results of univar-
iate analyses of the individuals who died
or survived are shown in supplementary
Table 1 (available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-1215/DC1). In univar-
iate Cox regression analyses evaluating
325 deaths in 12,930 person-years, in-
creasing age, diabetes, decreasing pulmo-
nary function, and a high-risk CFTR class
were all associated with an increased risk
of death. Diabetes was associated with a
fourfold increase in risk of death relative
tothatinthosewithoutdiabetes(HR4.04
[95% CI 3.23–5.07], P  0.001). In uni-
variate analyses, infection with P. aerugi-
nosa, B. cepacia complex, H. inﬂuenzae, or
A. fumigatus; use of corticosteroids; the
presence of ABPA; use of nutritional sup-
plements; and decreased BMI Z score
were all associated with an increased risk
of death. Other characteristics that dif-
fered between subjects who died and
those who survived were a history of liver
disease, pancreatic insufﬁciency, and a
history of organ transplantation. Patients
with cystic ﬁbrosis whose disease had
beendetectedbyneonatalscreeninghada
lower risk of death compared with those
notdetectedthroughscreening,asdidin-
dividuals infected with S. aureus relative
to uninfected individuals. Not signiﬁ-
cantly associated with death in univariate
analyses were sex (P  0.057) and infec-
tion with methicillin-resistant S. aureus.
Given the relationship between com-
plications, we evaluated the independent
role of each risk factor in multivariate
modeling. The ﬁnal age-adjusted model
showed an increased risk of death associ-
ated with each of the following: diabetes,
decreasing pulmonary function, female
sex, decreasing BMI Z score, infection
with B. cepacia complex, diagnosis of
ABPA, history of liver disease, prior organ
transplantation, and the use of corticoste-
roids(Fig.3).InfectionwithS.aureuswas
independently associated with a de-
creased risk of death. Diabetes was asso-
ciated with a 31% (95% CI 3–67)
increase in risk of death independent of
other complications of cystic ﬁbrosis. Fe-
Figure 2—Mortality rates with 95% CI by age and diabetes in patients with cystic ﬁbrosis.  ,
Patients without diabetes; f, patients with diabetes. *P  0.05, difference between individuals
with and without diabetes.
Table 1—Crude, directly standardized mortality rates (per 1,000 person-years) and SMRs by sex and diabetes in patients with cystic ﬁbrosis
Patients
(n)
Person-years
at risk Deaths (n)
Crude mortality rate
(95% CI)
Directly standardized
mortality rate (95% CI)* SMR (95% CI)*
Total 5,892 17,672 393 22.2 (20.1–24.6) 26.8 (19.0–40.5) 55.5 (40.8–70.1)
Male 3,155 9,425 191 20.3 (17.6–23.4) 23.5 (14.9–43.3) 39.8 (24.7–55.0)
Female 2,737 8,247 202 24.5 (21.3–28.1) 30.9 (19.0–56.5) 84.1 (53.4–114.7)
Diabetes 696 1,953 141 72.2 (61.2–85.1) 48.4 (27.7–106.2) 123.4 (74.7–172.1)
Male 349 970 61 62.9 (48.9–80.8) 41.9 (22.2–106.8) 82.2 (33.6–130.9)
Female 347 983 80 81.4 (65.4–101.3) 56.1 (24.0–209.8) 208.7 (99.4–318.0)
Without diabetes 5,196 15,718 252 16.0 (14.2–18.1) 20.6 (13.3–35.7) 42.4 (28.1–56.7)
Male 2,806 8,454 130 15.4 (12.9–18.3) 16.7 (9.5–41.4) 32.1 (16.9–47.2)
Female 2,390 7,264 122 16.8 (14.1–20.1) 25.4 (13.9–53.9) 60.4 (31.3–89.5)
*Using the 2005 population of England and Wales as a standard population.
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than male patients, with all other factors
being equal.
Including high- and low-risk geno-
type classes and pancreatic insufﬁciency
inthemultivariatemodeldescribedabove
did not render insigniﬁcant any factor or
change the HR for death associated with
diabetes. We found no interactions.
PAF of death in cystic ﬁbrosis
The estimated PAFs for mortality are
shown in supplementary Table 2. With
continuous variables coded as binary
variables, nutritional supplementation
was associated with an increased risk of
death. Of modiﬁable factors contributing
to mortality, poor pulmonary function
deﬁned as a predicted FEV1 70% ac-
countedforthegreatestproportionofrisk
at 78%. Low BMI (BMI Z score 0.23)
accounted for the next largest component
of risk. The PAF for diabetes was 14%
(95% CI 8–19).
CONCLUSIONS — Thisreporthigh-
lightsthespeciﬁccontributionofdiabetes
to mortality in Britain’s population with
cystic ﬁbrosis. Using nationally represen-
tativeandsystematicallycollecteddata,in
this report we estimate the absolute, rela-
tive, and attributable risk of death associ-
ated with diabetes. Because some of the
factors are potentially modiﬁable, then, if
they are also causal, this provides hope
and identiﬁes research targets to further
extend the lives of individuals with cystic
ﬁbrosis.
In Britain, where the incidence of di-
abetes in cystic ﬁbrosis approximates
2–7% per year (5), we estimate that dia-
betes accounts for some 14% of deaths.
That the components from PAF modeling
add up to 100%, although not an intu-
itive ﬁnding, assumes that risk factors in-
terrelate and that each risk factor is the
ﬁrst to be eliminated (14). This increased
risk associated with diabetes is not ex-
plained by previously identiﬁed risk fac-
tors for death including poor pulmonary
function (15), other complications (6),
sex(16,17),orgenotype(18),allofwhich
are also associated with an increased risk
of diabetes (5). It is likely that the meta-
bolic derangements associated with dia-
betes nonetheless predispose individuals
to infection, worsen pulmonary function,
and make maintenance of body weight
difﬁcult.
The present study showed a dispro-
portionately increased, albeit insigniﬁ-
cant, relative risk of death associated
with diabetes in children aged 10 years
relative to individuals aged 10 years.
Research in France has shown that indi-
viduals with cystic ﬁbrosis who develop
abnormal glucose metabolism as children
have higher mortality rates than those
who developed dysglycemia as adults
(19). In our study, of the children 10
years, only a very small proportion would
be expected to have autoimmune-
mediated diabetes (type 1), given the low
prevalenceintheU.K.generalpopulation
(20). Because screening for diabetes in
cystic ﬁbrosis in the U.K. is encouraged
foradultsduringperiodsofclinicalstabil-
ity but not for children aged 12 years,
diabetic children at presentation may
have more severe hyperglycemia. We
could not address degree of hyperglyce-
mia, duration of diabetes, or age of its on-
set in these analyses.
Registry data from the U.S. show that
diabetes, controlling for other factors, is
associated with a 55% increase in mortal-
ity risk in cystic ﬁbrosis (6); we estimate a
more modest 30% increase in risk. If we
acknowledge imprecision in estimates
and the potential misclassiﬁcation of dia-
betes, a real difference may exist. This
may represent in the U.K., relative to the
U.S., earlier detection of diabetes, less de-
tectionbias(diagnosingdiabetesinsicker
patients with more frequent medical at-
tention), or better glycemic control (for
which evidence linking better control to
mortality in cystic ﬁbrosis is sparse). A
differencecouldrepresentdifferentstatis-
tical models; the U.S. model does not in-
clude organ transplantation or use of
corticosteroids, both risk factors for dia-
betes (5) and, in this study, for death.
These ﬁndings imply that delaying
the onset of diabetes, possibly through
avoidance of corticosteroids, or assuring
earlierandbettertreatmentfordiabetesin
those with cystic ﬁbrosis may lengthen
survival.Yetnoevidenceforpreventionof
diabetes in cystic ﬁbrosis exists, and trials
of treatment are few (21). A randomized
trial of lowering blood glucose has shown
improvements in BMI, but not in pul-
monary function (22). In the general
population, weight loss and exercise
can prevent or delay onset of type 2 di-
abetes (23), but these factors have min-
imal relevance to cystic ﬁbrosis–related
diabetes, in which -cell dysfunction
and decreased insulin production pre-
dominate. In type 1 diabetes, trials of
early treatment to prevent diabetes have
failed (24,25).
For other risk factors for death, the
present study shows, consistent with oth-
ers (16), that female patients die earlier
than male patients. The increased risk of
deathinwomendoesnotappeartobedue
to a higher prevalence of complications;
rather it indicates that female patients
with a given set of comorbidities fared
worse than same-aged male patients with
the same problems. We conﬁrm that
lower BMI, pulmonary complications,
and infection with B. cepacia complex are
associated with an increased risk of death
in cystic ﬁbrosis and that infection with
S. aureus is associated with a decreased
Figure 3—Risk factors for death in cystic ﬁbrosis. Cox proportional hazards modeling adjusted
for age and all risk factors in the ﬁgure. n  4,234.
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by itself associated with death in cystic
ﬁbrosis, reﬂecting, perhaps, the fact that
death rates stabilized after age 20 years
(Figs. 1 and 2). Our models incorporated
age-dependent variables (percent pre-
dicted FEV1 and BMI Z score); when
modeling was done instead with absolute
values for FEV1 and BMI, increasing age
was associated with an increased death
rate. Separate analyses for children and
adults (age 16 vs. 16 years) showed
that in multivariate modeling, pulmonary
function was associated with mortality in
both groups, whereas BMI was associated
with mortality only in adults. We do not
know of another study showing that cor-
ticosteroids are associated with an in-
crease in the risk of death independent of
other complications. For oral corticoste-
roids, there is evidence of a short-term
beneﬁt in pulmonary function, but the
balance of risk in the long term is not
clear. Physicians may simply offer corti-
costeroids to patients with the greatest
risk of dying.
The high SMRs we report reconﬁrm
that mortality in the cystic ﬁbrosis popu-
lation in Britain far exceeds that of the
general population (4). For individuals
with diabetes, these values are higher at
nearly 120 times those for the general
population. Our ﬁndings from directly
standardizedmortalityratesshowthatthe
cystic ﬁbrosis population in the U.K.,
with a median age of 13 years, has a mor-
tality rate similar to that of those aged
70–74 years in the general population of
England and Wales (12).
The strengths of this study are its size
and its systematically collected longitudi-
nal data. Potential limitations include as-
certainment of death from the registry
rather than from death records and pos-
sible misclassiﬁcation of individuals with
diabetes. Underdetection of diabetes is
probably lessened by universal and free
access to health care in Britain. If unwell
individuals with stress hyperglycemia
were labeled as diabetic, this would sug-
gest that the value for risk associated with
diabetes we report underestimates the
truth. Likewise, if factors associated with
the risk of death were more apt to be de-
tected in the sickest patients, the relative
risks we report would overestimate the
true associations but would not bias the
overall mortality rates.
In summary, this report documents
recent mortality statistics for adults and
children with cystic ﬁbrosis in Britain. In
this study, we identify complications in-
cluding diabetes that, if delayed or better
treated, might reasonably extend the lives
of individuals with cystic ﬁbrosis in the
U.K. Advances in life expectancy to date
support this opportunity, whereas the
PAF quantiﬁes potential gains.
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